Identifying G protein-coupled receptor dimers from crystal packings

Authors

Ronald E. Stenkamp^{a*}

^aDepts. of Biological Structure and Biochemistry, Biomolecular Structure Center, University of Washington, Box 357140, Seattle, Washington, 98112, United States

Correspondence email: stenkamp@u.washington.edu

Synopsis Analysis of intermolecular interactions in G protein-coupled receptor crystal structures shows two major types of dimers.

Abstract Dimers of G protein-coupled receptors are believed to be important for signaling with their associated G proteins. Low resolution electron microscopy shows rhodopsin dimers in native retinal membranes, and CXCR4 dimers are found in several different crystal structures. Evidence for dimers of other GPCRs is more indirect. An alternative to computational modeling studies is to search for parallel dimers in the packing environments of the reported crystal structures of GPCRs. Two major structural types of GPCR dimers exist (as predicted by others), but there is considerable structural variation within each cluster. The different structural variants described here might reflect different functional properties and should provide a range of model structures for computational and experimental examination.

Keywords: G protein-coupled receptors; dimers; crystal packing interactions.

1. Introduction

Do G protein-coupled receptor (GPCR) dimers exist, and if they do, what do they look like? These are long-standing questions important for understanding GPCR function. Images of ordered arrays of rhodopsin in native membranes (Fotiadis *et al.*, 2003, Liang *et al.*, 2003, Filipek *et al.*, 2004, Fotiadis *et*

et al., 2006) are consistent with dimers and higher oligomers, and electron microscopic studies of transducin/rhodopsin complexes further indicate that rhodopsin dimers exist and are physiologically functional (Jastrzebska *et al.*, 2011, Jastrzebska *et al.*, 2013). Other GPCRs are also believed to form dimers (Palczewski & Orban, 2013, Ferre *et al.*, 2014, Kasai & Kusumi, 2014, Vischer *et al.*, 2015, Gahbauer & Böckmann, 2016, Farran, 2017, Tian *et al.*, 2017).

Crystal structure determinations of GPCRs have shown their basic protein folding topology of seven transmembrane helices (TM1 through TM7), and in some GPCRs, an eighth helix (H8) oriented parallel to the membrane surface. Analysis of crystal packing interactions (Katritch *et al.*, 2013) led to the suggestion of two possible interfaces involved in dimer formation. One such interface involves transmembrane helices TM1 and TM2 as well as helix H8. Another interface of interest makes use of TM3, TM4, TM5 and TM6. These interfaces are small in area, with no amino acid residues sufficiently buried to be considered “core” residues. Computational analysis of these interfaces (Duarte *et al.*, 2013) suggests that most of them do not result in physiologically relevant dimers. More recently, Baltoumas, *et al.* (Baltoumas *et al.*, 2016) used molecular dynamics calculations to investigate the stability and dynamics of potential dimers extracted from crystal structures along with dimers modeled de novo. Their results are consistent with these two major candidates for dimer interfaces.

Over 200 crystal structures of GPCRs have been deposited in the Protein Data Bank (PDB) (Berman *et al.*, 2000) since the structure of rhodopsin was solved in 2000 (Palczewski *et al.*, 2000). This project investigates whether there are examples of GPCR-GPCR interactions in crystals that can be models of functional GPCR dimers. These might provide starting points for computational modeling or other experimental approaches probing for physiological dimers of biomedical interest. Reported here are the results of looking for GPCR dimers in the crystal structures.

2. Materials and Methods

A list of GPCR crystal structures was assembled by collating the results of keyword searches at the PDB website and lists found in review articles (Okada, 2012, Piscitelli *et al.*, 2015) and in GPCR database websites (GPCRdb, <http://gpcrdb.org/> (Isberg *et al.*, 2016); Membrane Proteins of Known 3D Structure, <http://blanco.biomol.uci.edu/mpstruc/>). Table 1 lists the 215 entries in the initial set of crystal structures and the 121 crystal forms containing GPCR transmembrane domains.

The deposited structural models include many non-protein moieties such as crystallization agents, ligands, agonists, antagonists, post-translational modifications, and peptide or protein inhibitors. Non-covalently bound groups were removed from the structural models since the focus of this study is on protein-protein interactions that might mimic subunit interactions in dimers.

Crystal packing environments for the GPCR molecules were generated and analyzed using a mix of programs in the CCP4 program suite (Winn *et al.*, 2011) and locally written programs. Space group symmetry operations were applied using `pdbsym` to generate the molecules surrounding each GPCR in their crystalline lattice. Molecules were considered part of the packing environment for each crystallographically unique GPCR if they had atoms within 4.0 Å of atoms in the central (or base) molecule. The CCP4 superpose program (Krissinel & Henrick, 2004) was used to align the environments on the basis of the central GPCRs. The packing environments were further dissected to generate pairs of interacting GPCRs. For each pair, buried solvent accessible surfaces (bSAS) were calculated using `areaimol` (Lee & Richards, 1971, Saff & Kuijlaars, 1997).

XtalView (McRee, 1999) and Coot (Emsley *et al.*, 2010) were used for molecular visualization. Figures were generated using XtalView (McRee, 1999), MOLSCRIPT (Kraulis, 1991) and Raster3d (Merritt & Bacon, 1997).

3. Results and Discussion

As of November 1, 2017, models for 215 GPCR crystal structures were available in the PDB. If two structures were of the same GPCR with similar unit cell dimensions and identical space group assignments, they were considered isomorphous. For each set of isomorphous structures, the one with the highest resolution was chosen as the exemplar for that crystal form. The assignment of isomorphous structures was not confirmed by comparison of diffraction patterns.

There are 121 unique crystal forms, some of which contain more than one molecule in the asymmetric unit, and this leads to 173 crystallographically unique GPCR molecules, i.e., GPCRs found in different packing environments. The number of close neighbors for each of those varies from 0 to 12 GPCR molecules. (For some of the structures where a GPCR is co-crystallized with other proteins, e.g., its G protein or a crystallization chaperone, there may be no or few GPCR-GPCR interactions.) A 400 Å² cutoff in buried solvent accessible surface areas (bSAS) per protein molecule limited the pairs of GPCRs for further consideration to 319 (out of 1033 possible) even though the cutoff is significantly smaller than the bSAS values for biologically significant oligomers (Janin, 1997). The bSAS calculations were carried out largely to identify the molecular regions involved in GPCR-GPCR interactions.

The pairs of GPCRs were inspected visually and classified into four groups, parallel dimers, antiparallel dimers, crisscross dimers, and others (see Table 1). 71 pairs contained GPCRs oriented parallel to one another as you would expect for pairs that could possibly interact within a membrane. The exact orientation of these molecules with respect to a membrane is unknown, as is the membrane's location relative to the long axis of the molecules. The membrane is assumed to be roughly perpendicular to the axes of the transmembrane helices. In that case, the molecules in these “parallel” orientations would have their N- termini on one side of the membrane and their C-termini on the other.

137 of the interfaces involve pairs of receptors with the helices of one GPCR opposite in orientation relative to the other GPCR. Twenty interfaces contain molecules with their transmembrane domains roughly perpendicular to each other. Finally, there are 91 interfaces not involving contacts between the

transmembrane domains. Many of the crystal structures are of GPCRs fused with other proteins to enhance their stability and/or crystallization properties. The interactions holding the crystals together in some cases are between the intra- and extra-cellular loops and the fusion domains. Some of these represent modes of interaction that might be found in native membranes, but they have been omitted from this study.

The 71 interfaces with GPCRs in parallel orientations will be called dimers for convenience, but it should be remembered that it is unknown if they form stable complexes in membrane environments. The molecules forming each dimer are listed in Tables 2 and 3 along with information allowing their identification in the PDB. The first molecule listed for a dimer is considered the base or central molecule used for superpositions of the dimers.

The GPCRs in the parallel dimers are related by combinations of rotations and translations. The 29 interfaces listed in Table 2 involve GPCRs not related by two-fold rotation axes. Eleven of the interfaces involve proteins related by translational symmetry with rotations of 0.0° or 2.2° . Four of the eleven interfaces have two entries in the table because both molecules forming the interface bury more than $400 \text{ \AA}^2$ of bSAS. The other three interfaces have only one entry each in the table because one of the two GPCRs buries less than $400 \text{ \AA}^2$ in the interface. The interactions involved in all eleven are heterologous, and when repeated, lead to infinite oligomers, not discrete dimers. However, these arrays might account for those observed for rhodopsin in native membranes (Liang *et al.*, 2003).

There are 18 parallel interfaces involving molecules related by approximate or exact three-, four-, and six-fold rotational axes perpendicular to the assumed membrane plane. These interactions are also heterologous, so again the interfaces appear twice in Table 2. There are three interfaces between molecules related by approximate six-fold rotation axes, and one with exact six-fold symmetry. Four interfaces have approximate four-fold symmetry, and one has exact three-fold rotational symmetry. The exact rotation axes result in a cyclic hexamer or cyclic trimer. Subunits related by approximate n-fold

axes do not form closed cyclic oligomers. Slight conformational changes could result in these approximate symmetry axes becoming to exact rotations, in which case, additional cyclic oligomeric forms might be generated.

The 42 remaining parallel interfaces contain GPCRs with transmembrane domains related by two-fold rotational symmetry axes perpendicular to the membrane plane. Crystallographic two-fold axes relate the GPCRs in 20 of these interfaces, and because the interfaces were generated for each of the crystallographically unique GPCRs, these interfaces appear only once in Table 3.

Twenty-two pairs involve non-crystallographic two-fold axes and appear twice in the table. Strictly speaking, the interactions between the molecules in these dimers are heterologous. The two molecules in a dimer are not crystallographically identical, and the inter-protein interactions are not entirely symmetric. However, most of the angles of rotation relating the pairs of molecules are close to 180° (the largest deviation from 180° being 3.4°). Comparison of the bSAS for the molecules in these dimers show that for eight of the pairs, the difference in bSAS between the two interacting molecules is less than 5% of the larger bSAS value. The molecules in these eight pairs appear to be nearly identical, so the one with the larger bSAS, has been used as the archetype for this dimer. For three of the interfaces (labelled 13, 21, and 27 in Table 3), larger differences in the bSAS for the molecules involved indicate that these interactions are more heterologous. To avoid over-counting of particular structures, only the GPCR with the larger bSAS will be considered further.

Figure 1 displays the result of superposing the 31 dimers listed in Table 3 that contain GPCRs related by two-fold rotation axes. The dimers were oriented by superposing the helices of each base molecule on the transmembrane helices of chain A of PDB entry 4X1H (Blankenship *et al.*, 2015) (opsin). A line connecting the centers of mass of the molecules in each pair was generated (see Figure 1a), and all 31 lines are shown in Figure 1b.

Dimers 1-13 (see listing in Table 3) form a cluster on the right of Figure 1b and contain receptors interacting mainly through helices TM1, TM2 and H8. Those on the left (14-31) are formed by interactions between helices TM3, TM4, TM5, and TM6. Table 4 lists the helices in the base molecules forming contacts in the dimer interfaces, and Table 5 lists the specific residues in the base molecules involved in each interface.

Identification of these general inter-helical interactions is not a new observation. Katritch, Cherezov and Stevens commented on several crystallographic dimers (Katritch *et al.*, 2013), and Baltoumas, Theodoropoulou and Hamodrakas included 16 crystallographic and computationally modeled dimers in their molecular dynamics study (Baltoumas *et al.*, 2016). The systematic search described here provides additional crystallographic examples of possible dimers. This larger set of examples shows the range of structures in the two clusters of dimers.

While the subunits in dimers 1-13 mainly interact via helices TM1, TM2 and H8, the relative orientation of the two-fold rotation axes relating the subunits in these dimers varies across the set. The subunits in dimers 1, 2, 3, 4, and 5 are arranged such that their two-fold axes are parallel to the long axes of the central receptor shown in Figure 1. Figure 2a is a view of dimer 4, looking approximately down its two-fold rotation axis and is representative of this group of dimers. In this group, H8 from the left subunit is above that from the right subunit, see Figure 2b.

Dimers 6, 10, and 11 form another group with their two subunits twisted about the line between their centers when compared to the dimers in the first group (compare Figure 2c and 2a). As seen for dimer 6, the positions of H8 switch such that H8 from the left subunit is now below that from the right (Figure 2d). This structural difference positions the opposite side of the helix for subunit-subunit interactions compared to the dimers represented in Figure 2a.

A third set of dimers (7, 8, and 9) also contain subunits twisted about their line of centers relative to the first group (see Figure 2e), however, the sense of this twist is opposite to that of the second group.

Associated with this different twist, H8 from the left subunit is again above that from the right (see Figure 2f). In dimers 12 and 13, there are no H8 helices, and this relaxes any restraint the helix places on subunit-subunit orientation. The connection between the orientation of the subunits and the position of H8 in the interface was made by Baltoumas, *et al.* (Baltoumas *et al.*, 2016), and the role of H8 in GPCR functioning has been noted (Sato *et al.*, 2016) with a focus on its interactions with other structural elements of its GPCR and on interactions between the GPCR and G proteins. It is also possible that amino acid sequence differences or physical conditions controlling helix folding of H8 might modulate signaling by affecting the role of H8 in the dimer interface.

On the other side of Figure 1b, the interfaces for dimers 14-31 are formed by inter-helical interactions involving TM3, TM4, TM5, and/or TM6 (see Figure 3 and Table 4). These structures cover a broad range of orientations, but they can also be grouped according to the locations of the two-fold rotation axes relating their subunits. The transmembrane helices in the subunits for these dimers are all roughly perpendicular to the membrane plane, but the rotation axes are found at different positions around the surface of the central molecule. This results in a systematic variation in the helices forming the dimer interactions (see Figure 3). Dimer 18 is representative of dimers 16-20 (see Figure 3a) where TM3, TM4 and TM5 are found at its interface. Dimer 24 is near the center of dimers 21-27 (Figure 3b) where TM6 joins the set of interacting helices. Finally, for dimers 28 (Figure 3c), the dimeric interface has moved along the surface to the point where neither TM4 nor TM6 makes contacts between the subunits. As is the case for dimers 1-13, considerable structural variation is found in interfaces for dimers 14-31, enough to provide several possible beginning points for homology modeling projects.

The residues in the transmembrane helices in the dimer interfaces are listed in Table 5. As expected for interactions between transmembrane helices, most of the residues involved are hydrophobic. At the ends of the helices, hydrophilic residues can form hydrogen bonds with other polar groups, and a few polar residues are also found in the central parts of the helices. Identification of residue positions that might be crucial for inter-subunit interactions is complicated by multiple occurrences of particular GPCRs in Table

5. For example, while residue position 1x40 (GPCRdb numbering (Isberg *et al.*, 2016)) is located in the interfaces of nine dimers, if β_1 adrenergic receptor and rhodopsin are counted only once, that number drops to five. Similarly, counting of the CXCR4 dimers only once significantly changes the number of times residues such as 3x51 or 5x38 are found at dimer interfaces.

While the orientation of the GPCRs in the interfaces reported here is consistent with them being in natural membranes, it is not clear that the observed inter-GPCR interactions are strong enough to be biologically relevant. Contributions of “core” residues in stabilizing inter-molecular contacts are major considerations in the eppic webserver (<http://www.eppic-web.org/ewui/#>) (Duarte *et al.*, 2012) designed to determine oligomeric states of membrane proteins. Most of the dimers listed in Table 3 have small bSAS, and there are few, if any, “core” residues in their interfaces. eppic suggests that the interfaces found in the 31 possible dimers are characteristic of crystal packing interfaces and not biologically relevant ones. Post-translational modifications and bound ligands further complicate this issue since they can stabilize the dimer interactions. Views of the interactions of these moieties with GPCRs are difficult to find since only a few of the low or moderate resolution crystal structure models include these groups.

While none of the entries in Table 3 appear to involve extensive biologically relevant interfaces, it is noteworthy that CXCR4 appears in the table six times (dimers 21-24, 26, 27). As noted in the original structure reports (Wu *et al.*, 2010, Qin *et al.*, 2015), a CXCR4 dimer is found in six different crystal packing arrangements, i.e., six different crystal forms. The six CXCR4 entries in Table 3 form a tight cluster in Figure 1b, and the structures are similar (see Figure 3b). These dimers make use of TM3, TM4, TM5, and TM6 in their inter-subunit interfaces.

Another receptor that appears several times in Table 3 is the β_1 -adrenergic receptor (Huang *et al.*, 2013, Warne *et al.*, 2008, Moukhametzianov *et al.*, 2011, Miller-Gallacher *et al.*, 2014). In dimers 5, 6, and 11, TM1 and TM2 form the major interactions between the subunits. Dimers 6 and 11 are similar, but their subunits are oriented differently from those in dimer 5 (see Figure 2). β_1 -adrenergic receptor dimers can

also be formed by interactions using TM3, TM4 and TM5 (dimer 25). As opposed to the case of CXCR4 where the same interaction mode between GPCRs is seen in several crystal packing arrangements, fundamentally different dimers of β_1 -adrenergic receptor need to be considered for studies of its oligomerization.

Rhodopsin/opsin dimers appear four times in Table 3 (numbers 1, 7, 8, and 9). Dimer 1 is formed by subunits that are nearly aligned. Dimers 7, 8, and 9 are similar in structure with subunits twisted relative to one another (Figure 2e). TM1 and TM2 form part of the subunit interfaces in all four dimers. Residues from TM6, TM7 and H8 are found at the interface in dimer 1, while dimer 8 also makes use of TM7 and H8 in its dimer interface. Low resolution electron microscopic, computational (PDB entry 1N3M), crosslinking, and mutagenesis studies (Liang *et al.*, 2003, Jastrzebska *et al.*, 2011, Jastrzebska *et al.*, 2016) resulted in the development and support of a rhodopsin dimer (PDB entry 1N3M) that utilizes TM4 and TM5 in the dimer interface. While this type of dimer is not consistent with the pairs seen in the rhodopsin/opsin crystal structures, it is like dimers 17-25.

4. Conclusions

Two major types of GPCR dimers deduced from their crystal structures have been identified by others (Katritch *et al.*, 2013, Baltoumas *et al.*, 2016). Previous studies have focused on particular receptors and their possible oligomers. What is unclear from the published records is whether all packing interactions in known GPCR crystal structures have been considered in those studies. The larger number of experimentally determined GPCR crystal structures available now provides an opportunity to see how varied the members of those clusters are.

In the case of the dimers formed by interactions involving TM1 and TM2, twisting of the subunits around the line between their centers affects the overall relative orientations of the subunits. In addition, this has a major effect on H8 and how it interacts with other parts of its

own GPCR and/or its dimeric mate. These structural differences might be associated with the effects of H8 on GPCR function.

Because of the recurring CXCR4 dimers and the rhodopsin modeling, the TM3-6 interface has been the focus of much attention. However, not all GPCR dimers based on this interface make use of it in the same way. There is a continuum of structures using portions of this interface because it covers such a large part of the protein's transmembrane surface. The variation can be seen in Table 4 where dimers 14-18 mainly have TM3-5 between the subunits, dimers 19-29 use TM3-6, and finally dimers 30-31 are stabilized by interactions of TM5 and TM6. The different pieces of this surface used in forming dimers is a complication of some importance because it expands the number of possible beginning models for computational studies of GPCR dimerization.

Examination of all of the dimeric crystal packing interactions also shows that only certain parts of the transmembrane surfaces of GPCRs are involved in forming parallel dimers. This appears as the systematic split in the dimers in Figure 1b. It is apparent from comparing interfaces from the crystal structures that not all combinations of transmembrane helices can lead to stable dimers. This restriction on which helices form dimeric interfaces is a powerful restraint to be considered in modeling GPCR dimers.

Figure 1 Schematic showing locations of lines-of-center of dimer subunits. (a) Two GPCRs in a dimer with a line joining their centers viewed perpendicular to the plane of the membrane. TM1 shown in blue, TM2 in dark green, TM3 in chartreuse, TM4 in yellow, TM5 in gold, TM6 in orange, TM7 in red, and H8 in cyan. The colors for the second subunit are the same, but in transparent mode. (b) Similar plot, but showing the lines connecting the centers of each of the 31 parallel dimers showing two-fold rotational symmetry (see Table 3).

Figure 2 Selected dimers formed using TM1-3 at their interfaces. The central and second molecules are shown as transparent red or blue alpha carbon tracings. Transmembrane helices at the interface are shown in bold colors. TM1 shown in blue, TM2 in dark green, TM3 in chartreuse. H8 from the central and second molecules shown in cyan and brown. (a) Dimer 4 looking down on the extracellular side of the GPCRs. (b) Same view of dimer 4, but clipped to show H8. (c) Dimer 6. (d) Same view as in (b). (e) Dimer 7. (f) Same view as in (b).

(a)

(b)

(c)

Figure 3 Selected dimers formed using TM3-6 at their interfaces. The central molecule is shown as a transparent red alpha carbon tracing. The second molecule is shown in transparent blue. Transmembrane helices at the interface are shown in bold colors. TM3 in chartreuse, TM4 in yellow, TM5 in gold, TM6 in orange. (a) Dimer 18 looking down on the extracellular side of the GPCRs. (b) Dimer 24. (c) Dimer 28.

Table 1 Crystal forms and GPCR-GPCR interactions. The PDB identification code for the exemplar structure is given for each crystal form. The number of packing interfaces is provided for each crystallographically unique GPCR chain in that structure. The numbers of parallel, antiparallel, crisscross and other interfaces as well as the interfaces with bSAS values less than 400 Å² are also listed. The last column contains PDB identification codes for isomorphous structures.

Crystal form	Molecule	PDB code	Resolution, (Å)	Reference	GPCR chain	# interfaces	# parallel	# antiparallel	# crisscross	# other	# too small	Isomorphous PDB entries
tc-01	β ₁ adrenergic receptor	2VT4	2.7	(Warne <i>et al.</i> , 2008)	A	7	1	0	1	1	4	
					B	7	0	0	1	1	5	
					C	7	0	0	1	1	5	
					D	7	1	0	1	1	4	
tc-02	CXCR4 chemokine receptor	3OE8	3.1	(Wu <i>et al.</i> , 2010)	A	9	3	0	0	0	6	
					B	9	3	0	0	0	6	
					C	8	2	0	0	0	6	
tc-03	CXCR4 chemokine receptor	3OE9	3.1	(Wu <i>et al.</i> , 2010)	A	6	1	0	0	1	4	
					B	6	1	0	0	0	5	
tc-04	M ₃ muscarinic acetylcholine receptor	4DAJ	3.4	(Kruse <i>et al.</i> , 2012)	A	4	0	1	0	1	2	
					B	4	0	1	0	0	3	
					C	4	0	1	0	0	3	
					D	4	0	1	0	1	2	
tc-05	P2Y ₁ receptor	4XNW	2.7	(Zhang, Gao, <i>et al.</i> , 2015)	A	7	0	2	0	1	4	
					C	7	0	2	0	1	4	
tc-06	smoothed receptor	5L7I	3.3	(Byrne <i>et al.</i> , 2016)	A	12	0	1	0	1	1	
					B	10	0	1	0	0	9	
tc-07	CCR9 chemokine receptor	5LWE	2.8	(Oswald <i>et al.</i> , 2016)	A	5	2	0	0	1	2	
					B	7	2	0	0	1	4	
tc-08	GLP-1 receptor	5VEW	2.7	(Song <i>et al.</i> , 2017)	A	5	0	2	0	0	3	5VEX
					B	5	0	2	0	0	3	
tc-09	protease-activated receptor 2	5NDD	2.8	(Cheng, Fiez-Vandal, <i>et al.</i> , 2017)	A	8	1	0	0	0	7	5NDZ
mo-01	β ₁ adrenoceptor	4AMJ	2.3	(Warne <i>et al.</i> , 2012)	A	4	0	0	1	3	0	2Y00 2Y01 2Y02 2Y03 2Y04 3ZPQ 3ZPR
					B	4	0	0	1	2	1	
mo-02	β ₁ adrenergic receptor	2YCW	3.0	(Moukhametzianov <i>et al.</i> , 2011)	A	4	0	0	1	2	1	4AMI
					B	4	0	1	0	2	1	

mo-03	M ₂ muscarinic acetylcholine receptor	3UON	3.0	(Haga <i>et al.</i> , 2012)	A	6	0	2	0	0	4	
mo-04	A _{2A} adenosine receptor	3EML	2.6	(Jaakola <i>et al.</i> , 2008)	A	10	0	2	0	0	8	3QAK
mo-05	CXCR4 chemokine receptor	3ODU	2.5	(Wu <i>et al.</i> , 2010)	A	9	1	4	0	0	4	
					B	7	1	4	0	0	2	
mo-06	β ₂ adrenergic receptor – Gs complex	3SN6	3.2	(Rasmussen, DeVree, <i>et al.</i> , 2011)	R	0	0	0	0	0	0	
mo-07	nociceptin/ orphanin FQ peptide receptor	5DHG	3.0	(Miller <i>et al.</i> , 2015)	A	4	0	3	0	0	1	4EA3 5DHH
					B	6	0	3	0	1	2	
mo-08	smoothened receptor	4O9R	3.2	(Weierstall <i>et al.</i> , 2014)	A	6	0	0	0	1	5	
mo-09	neurotensin receptor	4GRV	2.8	(White <i>et al.</i> , 2012)	A	10	0	2	0	0	8	
mo-10	A _{2A} adenosine receptor	4UHR	2.6	(Lebon <i>et al.</i> , 2015)	A	10	0	2	0	0	8	
mo-11	smoothened receptor	4JKV	2.45	(Wang, Wu, <i>et al.</i> , 2013)	A	6	1	0	0	1	4	
					B	8	1	0	0	1	6	
mo-12	M ₄ muscarinic acetylcholine receptor	5DSG	2.6	(Thal <i>et al.</i> , 2016)	A	12	0	2	0	1	9	
					B	12	0	2	0	0	10	
mo-13	CB ₁ cannabinoid receptor	5U09	2.6	(Shao <i>et al.</i> , 2016)	A	10	0	0	0	0	10	
mo-14	angiotensin II type 2 receptor	5UNF	2.8	(Zhang, Han, <i>et al.</i> , 2017)	A	9	0	1	0	0	8	5UNH
					B	9	0	3	0	0	6	
mo-15	smoothened receptor	5V56	2.9	(Zhang, Zhao, <i>et al.</i> , 2017)	A	8	1	0	0	1	6	5V57
					B	10	0	0	0	2	8	
mo-16	glucagon receptor	5XEZ	3.0	(Zhang, Qiao, <i>et al.</i> , 2017)	A	1	0	0	0	0	1	5XF1
					B	3	0	0	0	0	3	
mo-17	serotonin 2B receptor	5TUD	3.0	(Ishchenko <i>et al.</i> , 2017)	A	3	0	2	0	0	1	
					D	3	0	2	0	0	1	
mo-18	free fatty acid receptor 1	5TZY	3.22	(Lu <i>et al.</i> , 2017)	A	6	0	2	0	0	4	
mo-19	β ₁ adrenergic receptor	2YCX	3.25	(Moukhametzianov <i>et al.</i> , 2011)	A	6	0	0	1	1	4	
					B	6	0	0	1	1	4	
mo-20	β ₁ adrenergic receptor	2YCY	3.15	(Moukhametzianov <i>et al.</i> , 2011)	A	8	1	0	1	1	5	
					B	6	0	0	1	1	4	
mo-21	β ₁ adrenergic receptor;	2YCZ	3.65	(Moukhametzianov <i>et al.</i> , 2011)	A	7	0	0	1	0	6	
					B	6	0	0	1	0	5	
mo-22	A _{2A} adenosine receptor	2YDV	2.6	(Lebon <i>et al.</i> , 2011)	A	8	0	0	0	3	5	2YDO
mo-23	CXCR4 chemokine receptor	3OE0	2.9	(Wu <i>et al.</i> , 2010)	A	4	1	0	0	1	2	
mo-24	β ₂ adrenoceptor	3P0G	3.5	(Rasmussen, Choi, <i>et al.</i> , 2011)	A	4	0	2	0	0	2	
mo-25	A _{2A} adenosine receptor	3VG9	2.7	(Hino <i>et al.</i> , 2012)	A	1	0	0	0	0	1	3VGA
mo-26	β ₂ adrenergic receptor	2R4R	3.4	(Rasmussen <i>et al.</i> , 2007)	A	2	0	0	0	0	2	2R4S 3KJ6

mo-27	β_2 adrenergic receptor	2RH1	2.4	(Cherezov <i>et al.</i> , 2007)	A	9	0	0	0	0	9	5D5A 5D5B 5D6L
mo-28	μ -opioid receptor	4DKL	2.8	(Manglik <i>et al.</i> , 2012)	A	5	2	0	0	1	2	
mo-29	smoothened receptor	4QIN	2.6	(Wang <i>et al.</i> , 2014)	A	8	1	0	0	1	6	
mo-30	angiotensin receptor	4YAY	2.9	(Zhang, Unal, Gati, <i>et al.</i> , 2015)	A	8	0	0	0	0	8	
mo-31	P2Y ₁₂ receptor	4PY0	3.1	(Zhang, Zhang, Gao, Paoletta, <i>et al.</i> , 2014)	A	6	0	3	0	0	3	
mo-32	δ -opioid receptor	4N6H	1.8	(Fenalti <i>et al.</i> , 2014)	A	9	0	2	0	1	6	
mo-33	orexin receptor	4S0V	2.5	(Yin <i>et al.</i> , 2015)	A	7	0	2	0	1	4	
mo-34	P2Y ₁₂ receptor	4NTJ	2.62	(Zhang, Zhang, Gao, Zhang, <i>et al.</i> , 2014)	A	8	0	0	0	0	8	
mo-35	free fatty acid receptor 1	5TZR	2.2	(Lu <i>et al.</i> , 2017)	A	6	0	3	0	0	3	4PHU
mo-36	metabotropic glutamate receptor 5	4OO9	2.6	(Dore <i>et al.</i> , 2014)	A	10	0	1	0	0	9	5CGC 5CGD
mo-37	M ₃ muscarinic acetylcholine receptor	4U15	2.8	(Thorsen <i>et al.</i> , 2014)	A	4	0	1	0	0	3	4U16
					B	4	0	1	0	0	3	
mo-38	δ -opioid receptor	4RWD	2.7	(Fenalti <i>et al.</i> , 2015)	A	6	0	0	0	1	5	
					B	6	0	0	0	1	5	
mo-39	δ -opioid receptor	4RWA	3.28	(Fenalti <i>et al.</i> , 2015)	A	6	0	0	0	1	5	
					B	6	0	0	0	1	5	
mo-40	5-hydroxy-tryptamine _{1B} receptor	4IAR	2.7	(Wang, Jiang, <i>et al.</i> , 2013)	A	4	0	2	0	0	2	
mo-41	β_1 adrenergic receptor	5F8U	3.35	(Leslie <i>et al.</i> , 2015)	A	5	1	0	0	0	4	4GPO
					B	5	1	0	0	0	4	
mo-42	CB ₁ cannabinoid receptor	5TGZ	2.8	(Hua <i>et al.</i> , 2016)	A	6	0	0	0	1	5	
mo-43	smoothened receptor	5L7D	3.2	(Byrne <i>et al.</i> , 2016)	A	9	0	2	0	1	6	
					B	8	0	0	0	1	7	
mo-44	apelin receptor	5VBL	2.6	(Ma <i>et al.</i> , 2017)	B	4	0	1	0	1	2	
or-01	sphingosine 1-phosphate ₁ receptor	3V2Y	2.8	(Hanson <i>et al.</i> , 2012)	A	9	1	0	0	0	8	3V2W
or-02	β_2 adrenergic receptor	3PDS	3.5	(Rosenbaum <i>et al.</i> , 2011)	A	7	0	0	0	1	6	
or-03	neurotensin receptor	5T04	3.3	(Krumm <i>et al.</i> , 2016)	A	11	0	1	0	1	9	
or-04	protease-activated receptor 2	5NJ6	4.0	(Cheng, Fiez-Vandal, <i>et al.</i> , 2017)	A	5	0	0	0	0	5	
or-05	β_1 adrenoceptor	4BVN	2.1	(Miller-Gallacher <i>et al.</i> , 2014)	A	8	1	2	0	2	3	5A8E
or-06	neurotensin receptor	4XES	2.6	(Krumm <i>et al.</i> , 2015)	A	5	0	0	0	0	5	4XEE
or-07	angiotensin II type 2 receptor	5UNG	2.8	(Zhang, Han, <i>et al.</i> , 2017)	B	10	0	2	0	1	7	
or-08	CB ₁ cannabinoid receptor	5XRA	2.8	(Hua <i>et al.</i>)	A	9	0	2	0	1	6	5XR8

or-09	corticotropin-releasing factor receptor 1	4K5Y	2.98	(Hollenstein <i>et al.</i> , 2013)	A	5	0	1	0	0	4	
					B	6	1	1	0	0	4	
					C	3	2	0	0	0	1	
or-10	A ₁ adenosine receptor	5UEN	3.2	(Glukhova <i>et al.</i> , 2017)	A	5	1	0	0	0	4	
					B	4	0	0	0	0	4	
or-11	CCR5 chemokine receptor	5UIW	2.2	(Zheng <i>et al.</i> , 2017)	A	6	2	0	0	0	4	
or-12	β ₂ adrenergic receptor	5X7D	2.7	(Liu <i>et al.</i> , 2017)	A	10	0	0	0	0	1	3D4S 3NY8
or-13	dopamine D3 receptor	3PBL	2.89	(Chien <i>et al.</i> , 2010)	A	8	0	1	0	0	7	3NY9 3NYA
					B	4	0	1	0	0	3	
or-14	κ-opioid receptor	4DJH	2.9	(Wu <i>et al.</i> , 2012)	A	7	1	1	0	0	5	
					B	7	1	1	0	0	5	
or-15	smoothened receptor	4QIM	2.61	(Wang <i>et al.</i> , 2014)	A	10	0	0	0	2	8	
or-16	protease-activated receptor 1	3VW7	2.2	(Zhang <i>et al.</i> , 2012)	A	8	0	2	0	1	5	
or-17	β ₂ adrenoceptor	4LDE	2.79	(Ring <i>et al.</i> , 2013)	A	4	0	0	0	0	4	4QKX 4LDL
or-18	β ₂ adrenergic receptor	4GBR	3.99	(Zou <i>et al.</i> , 2012)	A	4	0	1	0	1	2	4LDO note 1
or-19	glucagon receptor	4L6R	3.3	(Siu <i>et al.</i> , 2013)	A	6	0	0	0	2	4	
or-20	A _{2A} adenosine receptor	4UG2	2.6	(Lebon <i>et al.</i> , 2015)	A	5	1	1	0	0	3	
					B	3	1	1	0	0	1	
or-21	neurotensin receptor 1	3ZEV	1.99	(Egloff <i>et al.</i> , 2014)	A	5	0	0	1	0	4	4BV0 4BWB
					B	3	0	0	1	0	2	
or-22	M ₂ muscarinic acetylcholine receptor	4MQT	3.7	(Kruse <i>et al.</i> , 2012)	A	2	0	0	0	0	2	
or-23	M ₂ muscarinic acetylcholine receptor	4MQS	3.5	(Kruse <i>et al.</i> , 2012)	A	2	0	0	0	0	2	
or-24	neurotensin receptor 1	4BUO	2.75	(Egloff <i>et al.</i> , 2014)	A	6	0	0	1	1	4	
					B	4	0	0	1	1	2	
or-25	metabotropic glutamate receptor 1	4OR2	2.8	(Wu <i>et al.</i> , 2014)	A	7	1	1	0	0	5	
					B	7	1	1	0	0	5	
or-26	CCR5 chemokine receptor	4MBS	2.71	(Tan <i>et al.</i> , 2013)	A	6	2	0	0	1	3	
					B	6	2	0	0	1	3	
or-27	lysophosphatidic acid receptor 1	4Z35	2.9	(Chrencik <i>et al.</i> , 2015)	A	8	2	0	0	0	6	4Z34 4Z36
or-28	M ₁ muscarinic acetylcholine receptor	5CXV	2.7	(Thal <i>et al.</i> , 2016)	A	4	0	2	0	0	2	
or-29	human rhodopsin	5W0P	3.0	(Zhou <i>et al.</i> , 2017)	A	8	1	0	0	1	6	4ZWJ 5DGY
					B	6	0	1	0	1	4	
					C	6	0	1	0	0	5	
					D	8	0	1	0	1	6	
or-30	OX1 orexin receptor	4ZJ8	2.75	(Yin <i>et al.</i> , 2016)	A	4	0	1	0	0	3	4ZJC
or-31	A _{2A} adenosine receptor – mini Gs complex	5G53	3.4	(Carpenter <i>et al.</i> , 2016)	A	1	0	0	0	1	0	
					B	1	0	0	0	1	0	

or-32	CCR2 chemokine receptor	5T1A	2.81	(Zheng <i>et al.</i> , 2016)	A	6	0	2	0	0	4	
or-33	lysophosphatidic acid receptor 6A	5XSZ	3.2	(Taniguchi <i>et al.</i> , 2017)	A	4	0	2	0	0	2	
or-34	glucagon receptor	5EE7	2.5	(Jazayeri <i>et al.</i> , 2016)	A	10	1	2	0	0	7	
or-35	β_2 adrenergic receptor	5JQH	3.2	(Staus <i>et al.</i> , 2016)	A	2	0	1	0	0	1	
					B	2	0	1	0	0	1	
or-36	5-hydroxy-tryptamine _{1B} receptor	4IAQ	2.8	(Wang, Jiang, <i>et al.</i> , 2013)	A	4	0	2	0	0	2	
or-37	A ₁ adenosine receptor	5N2S	3.3	(Cheng, Segala, <i>et al.</i> , 2017)	A	6	2	0	0	0	4	
or-38	squid rhodopsin	2ZIY	3.7	(Shimamura <i>et al.</i> , 2008)	A	2	1	1	0	0	0	
or-39	smoothened receptor	4N4W	2.8	(Wang <i>et al.</i> , 2014)	A	8	0	0	0	1	7	
or-40	A _{2A} adenosine receptor	5NM4	1.7	(Weinert <i>et al.</i> , 2017)	A	6	0	1	0	0	5	4E1Y 5JTB 5MZJ 5MZF 5N2R 5NLX 5NM2 5UVI 5IU4 5IU7 5IU8 5IUA 5IUB 5K2A 5K2B 5K2C 5K2D
or-41	human cyto-megalovirus GPCR US28	4XT3	3.8	(Burg <i>et al.</i> , 2015)	A	3	0	2	0	0	1	
or-42	5-hydroxy-tryptamine _{2B} receptor	4IB4	2.7	(Wacker <i>et al.</i> , 2013)	A	7	0	3	0	0	4	4NC3 5TVN
or-43	P2Y ₁₂ receptor	4PXZ	2.5	(Zhang, Zhang, Gao, Paoletta, <i>et al.</i> , 2014)	A	6	0	2	0	0	4	
or-44	endothelin ET _B receptor	5GLH	2.8	(Shihoya <i>et al.</i> , 2016)	A	7	0	0	0	0	7	
or-45	endothelin ET _B receptor	5X93	2.2	(Shihoya <i>et al.</i> , 2017)	A	9	0	2	0	1	6	5GLI
or-46	D ₄ dopamine receptor	5WIU	1.96	(Wang <i>et al.</i> , 2017)	A	9	0	1	0	1	7	5WIV
or-47	CXCR4 chemokine receptor	3OE6	3.2	(Wu <i>et al.</i> , 2010)	A	7	1	3	0	0	3	
or-48	A _{2A} adenosine receptor	3UZA	3.27	(Congreve <i>et al.</i> , 2012)	A	3	0	0	0	2	1	3PWH 3REY 3RFM 3U2C
or-49	CXCR4 chemokine receptor	4RWS	3.1	(Qin <i>et al.</i> , 2015)	A	4	1	0	0	0	3	
or-50	μ -opioid receptor	5C1M	2.1	(Huang <i>et al.</i> , 2015)	A	4	1	1	0	0	2	
te-01	bovine rhodopsin	1U19	2.2	(Okada <i>et al.</i> , 2004)	A	6	0	1	0	2	3	1F88 1HZX 1L9H 2G87 2HPY 2PED 3OAX
					B	6	0	1	0	3	2	
te-02	M ₃ muscarinic acetylcholine receptor	4U14	3.57	(Thorsen <i>et al.</i> , 2014)	A	4	0	1	0	1	2	
te-03	A _{2A} adenosine receptor	5UIG	3.5	(Sun <i>et al.</i> , 2017)	A	7	0	1	0	0	6	
te-04	human cyto-megalovirus GPCR US28	4XT1	2.89	(Burg <i>et al.</i> , 2015)	A	4	0	0	0	0	4	
te-05	histamine H ₁ receptor	3RZE	3.1	(Shimamura <i>et al.</i> , 2011)	A	8	0	0	0	0	8	

tg-01	angiotensin II type-1 receptor	4ZUD	2.8	(Zhang, Unal, Desnoyer, <i>et al.</i> , 2015)	A	8	0	0	0	0	8	
tg-02	bovine rhodopsin	2I36	4.1	(Salom <i>et al.</i> , 2006)	A	2	1	0	0	1	0	2I37
					B	2	1	0	0	1	0	
					C	3	1	0	0	1	1	
tg-03	δ -opioid receptor	4EJ4	3.4	(Granier <i>et al.</i> , 2012)	A	3	0	2	0	0	1	
tg-04	GLP-1 receptor	5NX2	3.7	(Jazayeri <i>et al.</i> , 2017)	A	5	0	1	0	2	2	
tg-05	bovine opsin	5TE5	4.0	(Gulati <i>et al.</i> , 2017)	A	5	0	0	0	0	5	
tg-06	endothelin ET _B receptor	5XPR	3.6	(Shihoya <i>et al.</i> , 2017)	A	5	0	2	0	1	2	
rh-01	P2Y ₁ receptor	4XNV	2.2	(Zhang, Gao, <i>et al.</i> , 2015)	A	8	2	0	0	0	6	
rh-02	bovine opsin	4X1H	2.29	(Blankenship <i>et al.</i> , 2015)	A	4	1	0	0	1	2	2X72 3CAP 3DQB 3PQR 3PXO 4A4M 4BEY 4BEZ 4J4Q 4PXF 5DYS note 2
rh-03	bovine rhodopsin	2I35	3.8	(Salom <i>et al.</i> , 2006)	A	3	1	0	0	1	1	
he-01	corticotropin-releasing factor receptor 1	4Z9G	3.18	(Dore <i>et al.</i> , 2017)	A	7	2	0	0	0	5	
					B	7	2	0	0	0	5	
					C	2	2	0	0	0	5	
he-02	squid rhodopsin	2Z73	2.5	(Murakami & Kouyama, 2008)	A	4	1	1	0	1	1	3AYM 3AYN 4WW3
					B	4	1	1	0	1	1	
he-03	bovine rhodopsin	3C9L	2.65	(Stenkamp, 2008)	A	5	0	1	2	0	2	note 3
he-04	bovine rhodopsin	3C9M	3.4	(Stenkamp, 2008)	A	5	0	1	1	0	3	note 4

Note 1. The fusion domain for PDB entry 4GBR is listed as chain B. Chain B was combined with chain A for this study.

Note 2. PDB entry 3CAP is included in crystal form rh-02. An alternative interpretation of that structure involves converting non-crystallographic symmetry to crystallographic symmetry operations.

Note 3. PDB entry 3C9L is an alternative model for PDB entry 1GZM.

Note 4. PDB entry 3C9M is an alternative model for PDB entry 2J4Y.

Table 2 Interfaces between parallel GPCRs not related by two-fold rotational symmetry. The central subunit is positioned as in the deposited PDB file. The symmetry operation is applied to the second chain's fractional coordinates. The rotation column is derived from the transformation relating the subunits' transmembrane helices. The buried solvent accessible surface (bSAS) values are for the central molecule and its transmembrane helices. Non-crystallographic (ncs) and crystallographic symmetry (cryst) are noted. Entries with no molecule name listed are the opposing faces for the interfaces listed immediately before them.

Molecule	PDB code	Reference	Central subunit	Second subunit	Symmetry operation	Rotation (°)	bSAS total	bSAS transmembrane helices	Symmetry
CXCR4 chemokine receptor	3OE8	(Wu <i>et al.</i> , 2010)	C	A	x,y+1,z	91.9	852.2	684.1	ncs
			A	C	x,y-1,z	91.9	761.1	507.0	ncs
corticotropin-releasing factor receptor 1	4K5Y	(Hollenstein <i>et al.</i> , 2013)	B	C	-x-1, y+1/2, 1/2-z	64.8	811.9	811.9	ncs
			C	B	-x-1,y-1/2,1/2-z	64.8	798.7	762.0	ncs
CXCR4 chemokine receptor	3OE8	(Wu <i>et al.</i> , 2010)	A	B	x,y,z	85.3	746.9	579.0	ncs
			B	A	x,y,z	85.3	657.6	596.7	ncs
CCR5 chemokine receptor	4MBS	(Tan <i>et al.</i> , 2013)	B	A	x+1,y,z	2.2	724.4	499.2	ncs
			A	B	x-1,y,z	2.2	656.3	574.1	ncs
CCR5 chemokine receptor	4MBS	(Tan <i>et al.</i> , 2013)	A	B	x,y,z	2.2	672.3	560.3	ncs
			B	A	x,y,z	2.2	660.0	625.3	ncs
lysophosphatidic acid receptor 1	4Z35	(Chrencik <i>et al.</i> , 2015)	A	A	x-1,y,z	0.0	668.8	591.3	cryst
			A	A	x+1,y,z	0.0	664.7	544.7	cryst
P2Y1 receptor	4XNV	(Zhang, Gao, <i>et al.</i> , 2015)	A	A	y-x,-x,z	120.0	541.0	536.0	cryst

			A	A	-y,x-y,z	120.0	489.9	486.7	cryst
CXCR4 chemokine receptor	3OE8	(Wu <i>et al.</i> , 2010)	A	B	x+1,y,z	85.3	499.9	333.2	ncs
			B	A	x-1,y,z	85.3	492.2	236.7	ncs
A _{2A} adenosine receptor	4UG2	(Lebo n <i>et al.</i> , 2015)	B	A	-x,y-1/2,1/2-z	84.2	455.8	319.6	ncs
			A	B	-x, 1/2+y, 1/2-z	84.2	413.2	197.9	ncs
CCR5 chemokine receptor	5NDD	(Chen g, Fiez-Vand al, <i>et al.</i> , 2017)	A	A	1+x,y,z	0.0	754.9	170.1	cryst
smoothened receptor	5V56	(Zhan g, Zhao, <i>et al.</i> , 2017)	A	A	1+x,y,z	0.0	404.8	127.1	cryst
CCR5 chemokine receptor	5UIW	(Zhen g <i>et al.</i> , 2017)	A	A	x-1,y,z	0.0	672.5	462.3	cryst
			A	A	1+x,y,z	0.0	676.5	586.2	cryst
glucagon receptor	5EE7	(Jaza yeri <i>et al.</i> , 2016)	A	A	x-1,y,z	0.0	424.8	301.8	cryst
corticotropin-releasing factor receptor 1	4Z9G	(Dore <i>et al.</i> , 2017)	A	A	y,y-x,z	60.0	932.7	826.0	cryst
			A	A	x-y,x,z	60.0	976.6	924.6	cryst
corticotropin-releasing factor receptor 1	4Z9G	(Dore <i>et al.</i> , 2017)	B	C	x,y,z	59.7	1072.9	1016.2	ncs
			B	C	1-y,1+x-y,z	60.3	877.2	786.5	ncs
corticotropin-releasing factor receptor 1	4Z9G	(Dore <i>et al.</i> , 2017)	C	B	x,y,z	59.7	944.0	826.4	ncs
			C	B	y-x,1-x,z	60.4	992.3	890.0	ncs

Table 3 Interfaces between parallel GPCRs related by two-fold rotational symmetry. The central subunit is positioned as in the deposited PDB file. The symmetry operation is applied to the second chain's fractional coordinates. The rotation column is derived from the transformation relating the subunits' transmembrane helices. The buried solvent accessible surface (bSAS) values are for the central molecule and its transmembrane helices. Non-crystallographic (ncs) and crystallographic symmetry (cryst) are noted. Entries with no molecule name listed are the opposing faces for the interfaces listed immediately before them. The dimer label column is used throughout the rest of the paper to identify the dimers.

Molecule	PDB code	Reference	Central subunit	Second subunit	Symmetry operation	Rotation (°)	bSAS total	bSAS transmembrane helices	Symmetry	Dimer label
bovine opsin	4X1H	(Blankenship <i>et al.</i> , 2015)	A	A	-x,y-x,-z-1	180.0	832.6	785.0	cryst	1
CCR9 chemokine receptor	5LWE	(Oswald <i>et al.</i> , 2016)	A	B	x,y,z+1	176.7	621.7	292.0	ncs	2
			B	A	x,y,z-1	176.8	592.5	282.0	ncs	
μ-opioid receptor	4DKL	(Manglik <i>et al.</i> , 2012)	A	A	-x-1,y,-z-1	180.0	575.1	443.7	cryst	3
κ-opioid receptor	4DJH	(Wu <i>et al.</i> , 2012)	A	B	x,y,z	177.9	1003.9	687.0	ncs	4
			B	A	x,y,z	177.9	980.4	664.0	ncs	
β ₁ adrenergic receptor	5F8U	(Leslie <i>et al.</i> , 2015)	B	A	x,y-1,z	179.3	798.9	376.1	ncs	5
			A	B	x,1+y,z	179.2	799.9	377.0	ncs	
β ₁ adrenergic receptor	2VT4	(Warme <i>et al.</i> , 2008)	A	D	x-1,y,z+1	178.4	818.9	700.3	ncs	6
			D	A	x+1,y,z-1	178.3	812.4	701.5	ncs	
bovine rhodopsin	2I35	(Salom <i>et al.</i> , 2006)	A	A	2/3+x-y, 4/3-y, 1/3-z	180.0	427.4	334.4	cryst	7

bovine rhodopsin	2I36	(Salom et al., 2006)	C	C	x,x-y,1-z	180.0	666.0	459.5	cryst	8
bovine rhodopsin	2I36	(Salom et al., 2006)	B	A	x,y,z	176.6	495.6	365.2	ncs	9
			A	B	x,y,z	176.6	485.2	377.9	ncs	
μ-opioid receptor	5C1M	(Huang et al., 2015)	A	A	-x,-y+1/2,z	180.0	560.6	442.4	cryst	10
β ₁ adrenergic receptor	2YCY	(Moukhamet ziano v et al., 2011)	A	A	-x,y,-z	180.0	720.5	593.3	cryst	11
adenosine A ₁ receptor	5N2S	(Chen g, Segal a, et al., 2017)	A	A	5/2-x,5/2-y,z	180.0	1397.5	426.0	cryst	12
metabotropic glutamate receptor 1	4OR2	(Wu et al., 2014)	B	A	x,y,z	178.7	561.6	280.5	ncs	13
			A	B	x,y,z	178.7	508.6	289.1	ncs	
sphingosine 1-phosphate receptor	3V2Y	(Hanson et al., 2012)	A	A	-x,1-y,z	180.0	773.3	277.7	cryst	14
CCR9 chemokine receptor	5LWE	(Oswald et al., 2016)	A	B	x,y,z	176.8	495.1	495.1	ncs	15
			B	A	x,y,z	176.8	493.2	436.1	ncs	
smoothened receptor	4JKV	(Wang, Wu, et al., 2013)	B	A	x,y,z	178.9	1203.2	1130.1	ncs	16
			A	B	x,y,z	179.0	1144.4	1026.1	ncs	
adenosine A ₁ receptor	5N2S	(Chen g, Segal a, et al., 2017)	A	A	2-x,1-y,z	180.0	856.5	544.7	cryst	17
adenosine A ₁ receptor	5UEN	(Glukhova et al., 2017)	A	A	x,1-y,2-z	180.0	835.1	835.1	cryst	18
smoothened receptor	4QIN	(Wang et al., 2014)	A	A	-x-1,y,-z	180.0	1268.7	1058.7	cryst	19
squid rhodopsin	2Z73	(Murakami &	B	B	1-x,1-y,z	180.0	516.3	417.7	cryst	20

		Kouyama, 2008)								
CXCR4 chemokine receptor	3ODU	(Wu <i>et al.</i> , 2010)	B	A	x,y,z	179.8	921.2	692.8	ncs	21
			A	B	x,y,z	179.8	793.6	687.3	ncs	
CXCR4 chemokine receptor	4RWS	(Qin <i>et al.</i> , 2015)	A	A	2-x,-y,z	180.0	802.6	689.1	cryst	22
CXCR4 chemokine receptor	3OE6	(Wu <i>et al.</i> , 2010)	A	A	-x,1-y,z	180.0	754.1	612.3	cryst	23
CXCR4 chemokine receptor	3OE0	(Wu <i>et al.</i> , 2010)	A	A	1-x,y,-z	180.0	1047.5	954.0	cryst	24
β_1 adrenoceptor	4BVN		A	A	-x-1,y,-z	180.0	646.9	539.6	cryst	25
CXCR4 chemokine receptor	3OE8	(Wu <i>et al.</i> , 2010)	C	B	x,y,z	176.8	578.1	538.3	ncs	26
			B	C	x,y,z	176.8	576.9	530.2	ncs	
CXCR4 chemokine receptor	3OE9	(Wu <i>et al.</i> , 2010)	A	B	x,y,z	178.5	943.5	720.6	ncs	27
			B	A	x,y,z	178.6	863.3	570.8	ncs	
squid rhodopsin	2Z73	(Mura kami & Kouyama, 2008)	A	A	1-x,1-y,z	180.0	620.2	397.1	cryst	28
squid rhodopsin	2ZIY	(Shimamura <i>et al.</i> , 2008)	A	A	x,-y,-z	180.0	690.1	430.0	cryst	29
μ -opioid receptor	4DKL	(Manglik <i>et al.</i> , 2012)	A	A	-x-1,y,-z	180.0	1452.1	1304.8	cryst	30
corticotropin-releasing factor receptor 1	4K5Y	(Hollenstein <i>et al.</i> , 2013)	C	C	x,-y,1-z	180.0	919.7	585.2	cryst	31

Table 4 Structural elements of the central molecule forming the dimer interface.

Dimer label (from Table 3)	TM1	TM2	TM3	TM4	TM5	TM6	TM7	H8
1	x	x				x	x	x
2	x							
3	x	x						x
4	x	x	x					x
5	x	x						x
6	x	x						
7	x	x						
8	x	x					x	x
9	x	x						
10	x	x						
11	x	x						
12	x	x						
13	x							
14			x	x				
15				x				
16			x	x	x			
17			x	x	x			
18			x	x	x			
19			x	x	x	x		
20				x	x			
21					x	x		
22			x	x	x			
23					x	x		
24			x	x	x	x		
25			x	x	x			
26					x	x		
27			x		x	x		
28			x		x			
29			x		x			
30					x	x		
31					x	x	x	

Table 5 Residues at the dimer interfaces. Generic GPCRdb numbering taken from <http://gpcrdb.org/>.

(a) Dimers 1-13. (b) Dimers 14-20. (c) Dimers 21-31.

(a).

Dimer label (see Table 3)	1	2	3	4	5	6	7	8	9	10	11	12	13
Residue number	bovine opsin	CCR9 chemokine receptor	μ -opioid receptor	κ -opioid receptor	β_1 adrenergic receptor	β_1 adrenergic receptor	bovine rhodopsin	bovine rhodopsin	bovine rhodopsin	μ -opioid receptor	β_1 adrenergic receptor	adenosine A ₁ receptor	metabotropic glutamate receptor 1
1x29				P56						M65			
1x32				P59	E41	E41							
1x33	S38			V60		A42				I69	A42		
1x34	M39												
1x35						M44							
1x36			M72	T63	S45	S45					S45		
1x37	A42	P53		A64	L46	L46					L46		
1x39				Y66									
1x40	F45	W56	S76	S67	A49	A49	F45		F45		A49		
1x41	L46	L57		V68		L50					L50		
1x43				F70		V52	I48				V52		
1x44		I60		V71	L53	L53	M49	M49	M49		L53	L1126	
1x47						V56		F52	F52		V56	V1129	
1x48								P53	P53			P1130	L605
1x51												V1133	L608
1x52												L1134	F609
1x55										Y91		W1137	L612
1x56													I613
1x59										R95			L616
1x60													Y617
2x55												A1165	

2x58				P113		P96					P96		
2x59				F114		F97							
2x61	L95			S116		A99					A99		
2x62			V126	T117		T100	Y96	Y96	Y96	V126	T100		
2x65	L99		L129	L120						L129			
2x66			M130		R104	R104		H100	H100	M130	R104		
3x20				F126									
6x32	E249												
6x35	R252												
7x43	T297												
7x47	V300												
7x48	Y301												
7x51	V304												
7x52	I305												
7x55								M308					
7x56	M309												
8x48									K311				
8x51				K338	R350			R314	R314				
8x54			F347	F341	F353								
8x55				R342	K354								
8x58			C351					L321					
8x59	C322		I352	F346				C322					

(b).

Dimer label (see Table 3)	14	15	16	17	18	19	20
Residue number	sphingosine 1-phosphate ₁ receptor	CCR9 chemokine receptor	smoothed receptor	adenosine A ₁ receptor	adenosine A ₁ receptor	smoothed receptor	squid rhodopsin
3x23	A115						
3x27	L119						
3x44			V333				
3x48			Y337				
3x51			H340			H340	
3x55				K1215			
3x59					R114		
4x35					M117		
4x36					V118		
4x37		K160					
4x40	F158	L163		R1227			
4x41		Y164		R1228			
4x43	F161					S358	
4x44		M167				Y359	
4x45			F360				
4x47	S165	F170	L362			L362	
4x48		T171	L363				
4x51		V174				S366	
4x52						L367	W162
4x54	L172						
4x55		A178	V370	V1242	V137	V370	L165
4x56			L371				W166
4x58			V373				
4x59		I181	A374		T141		
4x62			A377	V1249	F144		
4x63			V378	G1250	G145		
4x64					W146		

4x68					S150		
5x30					E153		
5x31					R154		
5x34							S195
5x35							T196
5x38			R398	E1283	E178	R398	S199
5x39			Y399			Y399	
5x41						A401	
5x411				Y1287	Y182		
5x42			G402		F183	G402	C203
5x421			F403			F403	
5x45			A406			A406	
5x46			P407	V1292	V187		L207
5x49						L410	
5x52						I413	
5x53			V414			V414	
5x56			Y417			Y417	
5x57			F418			F418	
5x60			R421			R421	
6x56						F474	

(c).

Dimer label (see Table 3)	21	22	23	24	25	26	27	28	29	30	31
Residue number	CXCR4 chemokine receptor	CXCR4 chemokine receptor	CXCR4 chemokine receptor	CXCR4 chemokine receptor	β_1 adrenoceptor	CXCR4 chemokine receptor	CXCR4 chemokine receptor	squid rhodopsin	squid rhodopsin	μ -opioid receptor	corticotropin-releasing factor receptor 1
3x51		Y135		Y135	Y140		Y135	Y134	Y134		
3x52				L136	L141						
3x55			T144								
3x56				H140	S145						
4x35		R146		R146							
4x41					R157						
5x32	N192			N192			N192				
5x33	D193		D193	D193		D193				W226	
5x34	L194		L194	L194		L194	L194			Y227	
5x35	W195		W195	W195		W195	W195				
5x37	V197	V197	V197	V197		V197	V197			N230	
5x38	V198	V198	V198	V198	A206	V198	V198			L231	
5x41	F201	F201	F201	F201	I209	F201	F201			I234	
5x42	Q202		Q202		A210	Q202	Q202				Y270
5x44										F237	
5x45	M205		M205		I213	M205	M205			I238	
5x46					I214						
5x48										I242	
5x49	L210	L210	L210	L210	I218	L210					
5x52							I213		L214	L246	
5x55										T249	
5x56								F218	F218		
5x58										Y252	
5x59								F221	F221	G253	
5x60								N222	N222		
5x61										M255	

5x62										I256	
5x63		S224			R232			M225	M225	L257	
5x64				K225	E233						
5x66									S228		
5x67		H228		H228				N229	N229		
5x70									K232		
6x35										R280	
6x38										L283	
6x42											P321
6x46											I325
6x49										T294	M328
6x50											L329
6x51											A330
6x53										I298	V332
6x57										I302	
6x60										L305	
6x61										I306	
6x62	L266		L266	L266		L266	L266				
6x63	L267		L267	L267		L267	L267				
7x27											E338
7x33											F344

Acknowledgements I'm grateful to David Salom, Beata Jastrzebska, Philip Kiser, Isolde Le Trong, David Lodowski, Kris Palczewski, Peter Brzovic, and Dave Teller for encouragement and discussions of this and other GPCR-related topics and to Jeff Godden for technical assistance with the figures.

References

- Baltoumas, F. A., Theodoroulou, M. C. & Hamodrakas, S. J. (2016). *J. Comput. Aided Mol. Des.* **30**, 489-512.
- Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N. & Bourne, P. E. (2000). *Nucleic Acids Res.* **28**, 235-242.
- Blankenship, E., Vahedi-Faridi, A. & Lodowski, D. T. (2015). *Structure* **23**, 2358-2364.
- Burg, J. S., Ingram, J. R., Venkatakrisnan, A. J., Jude, K. M., Dukupati, A., Feinberg, E. N., Angelini, A., Waghray, D., Dror, R. O., Ploegh, H. L. & Garcia, K. C. (2015). *Science* **347**, 1113-1117.
- Byrne, E. F. X., Sircar, R., Miller, P. S., Hedger, G., Luchetti, G., Nachtergaele, S., Tully, M. D., Mydock-McGrane, L., Covey, D. F., Rambo, R. P., Sansom, M. S. P., Newstead, S., Rohatgi, R. & Siebold, C. (2016). *Nature* **535**, 517-522.
- Carpenter, B., Nehme, R., Warne, T., Leslie, A. G. W. & Tate, C. G. (2016). *Nature* **536**, 104-107.
- Cheng, R. K. Y., Fiez-Vandal, C., Schlenker, O., Edman, K., Aggeler, B., Brown, D. G., Brown, G. A., Cooke, R. M., Dumelin, C. E., Dore, A. S., Geschwindner, S., Grebner, C., Hermansson, N.-O., Jazayeri, A., Johansson, P., Leong, L., Prihandoko, R., Rappas, M., Soutter, H., Snijder, A., Sundstrom, L., Tehan, B., Thornton, P., Troast, D., Wiggin, G., Zhukov, A., Marshall, F. H. & Dekker, N. (2017). *Nature* **545**, 112-115.
- Cheng, R. K. Y., Segala, E., Robertson, N., Deflorian, F., Dore, A. S., Errey, J. C., Fiez-Vandal, C., Marshall, F. H. & Cooke, R. M. (2017). *Structure* **25**, 1275-1285.
- Cherezov, V., Rosenbaum, D. M., Hanson, M. A., Rasmussen, S. G., Thian, F. S., Kobilka, T. S., Choi, H. J., Kuhn, P., Weis, W. I., Kobilka, B. K. & Stevens, R. C. (2007). *Science* **318**, 1258-1265.
- Chien, E. Y., Liu, W., Zhao, Q., Katritch, V., Han, G. W., Hanson, M. A., Shi, L., Newman, A. H., Javitch, J. A., Cherezov, V. & Stevens, R. C. (2010). *Science* **330**, 1091-1095.
- Chrencik, J. E., Roth, C. B., Terakado, M., Kurata, H., Omi, R., Kihara, Y., Warshaviak, D., Nakade, S., Asmar-Rovira, G., Mileni, M., Mizuno, H., Griffith, M. T., Rodgers, C., Han, G. W., Velasquez, J., Chun, J., Stevens, R. C. & Hanson, M. A. (2015). *Cell* **161**, 1633-1643.

- Congreve, M., Andrews, S. P., Dore, A. S., Hollenstein, K., Hurrell, E., Langmead, C. J., Mason, J. S., Ng, I. W., Tehan, B., Zhukov, A., Weir, M. & Marshall, F. H. (2012). *J Med Chem* **55**, 1898-1903.
- Dore, A. S., Bortolato, A., Hollenstein, K., Cheng, R. K. Y., Read, R. J. & Marshall, F. H. (2017). *Current Molecular Pharmacology* **10**, 334-344.
- Dore, A. S., Okrasa, K., Patel, J. C., Serrano-Vega, M., Bennett, K., Cooke, R. M., Errey, J. C., Jazayeri, A., Khan, S., Tehan, B., Weir, M., Wiggin, G. R. & Marshall, F. H. (2014). *Nature* **511**, 557-562.
- Duarte, J. M., Biyani, N., Baskaran, K. & Capitani, G. (2013). *Bmc Structural Biology* **13**.
- Duarte, J. M., Srebniak, A., Scharer, M. A. & Capitani, G. (2012). *BMC Bioinformatics* **13**, 334.
- Egloff, P., Hillenbrand, M., Klenk, C., Batyuk, A., Heine, P., Balada, S., Schlinkmann, K. M., Scott, D. J., Schutz, M. & Pluckthun, A. (2014). *Proc Natl Acad Sci U S A* **111**, E655-662.
- Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. (2010). *Acta Cryst.* **D66**, 486-501.
- Farran, B. (2017). *Pharmacological Research* **117**, 303-327.
- Fenalti, G., Giguere, P. M., Katritch, V., Huang, X. P., Thompson, A. A., Cherezov, V., Roth, B. L. & Stevens, R. C. (2014). *Nature* **506**, 191-196.
- Fenalti, G., Zatsepin, N. A., Betti, C., Giguere, P., Han, G. W., Ishchenko, A., Liu, W., Guillemin, K., Zhang, H., James, D., Wang, D., Weierstall, U., Spence, J. C., Boutet, S., Messerschmidt, M., Williams, G. J., Gati, C., Yefanov, O. M., White, T. A., Oberthuer, D., Metz, M., Yoon, C. H., Barty, A., Chapman, H. N., Basu, S., Coe, J., Conrad, C. E., Fromme, R., Fromme, P., Tourwe, D., Schiller, P. W., Roth, B. L., Ballet, S., Katritch, V., Stevens, R. C. & Cherezov, V. (2015). *Nat Struct Mol Biol* **22**, 265-268.
- Ferre, S., Casado, V., Devi, L. A., Filizola, M., Jockers, R., Lohse, M. J., Milligan, G., Pin, J. P. & Guitart, X. (2014). *Pharmacol. Rev.* **66**, 413-434.
- Filipek, S., Krzysko, K. A., Fotiadis, D., Liang, Y., Saperstein, D. A., Engel, A. & Palczewski, K. (2004). *Photochem Photobiol Sci* **3**, 628-638.
- Fotiadis, D., Jastrzebska, B., Philippsen, A., Muller, D.J., Palczewski, K., & Engel, A. (2006). *Curr. Opin. Struct. Biol.* **16**, 252-259.

- Fotiadis, D., Liang, Y., Filipek, S., Saperstein, D. A., Engel, A. & Palczewski, K. (2003). *Nature* **421**, 127-128.
- Gahbauer, S. & Böckmann, R. A. (2016). *Frontiers in Physiology* **7**, Article 494.
- Glukhova, A., Thal, D. M., Nguyen, A. T., Vecchio, E. A., Jorg, M., Scammells, P. J., May, L. T., Sexton, P. M. & Christopoulos, A. (2017). *Cell* **168**, 867-877.
- Granier, S., Manglik, A., Kruse, A. C., Kobilka, T. S., Thian, F. S., Weis, W. I. & Kobilka, B. K. (2012). *Nature* **485**, 400-404.
- Gulati, S., Jastrzebska, B., Banerjee, S., Placeres, A. L., Miszta, P. G., S., Gunderson, K., Tochtrop, G. P., Filipek, S., Katayama, K., Kiser, P. D., Mogi, M., Stewart, P. L. & Palczewski, K. (2017). *Proc. Natl. Acad. Sci. U. S. A.* **114**, E2608-E2615.
- Haga, K., Kruse, A. C., Asada, H., Yurugi-Kobayashi, T., Shiroishi, M., Zhang, C., Weis, W. I., Okada, T., Kobilka, B. K., Haga, T. & Kobayashi, T. (2012). *Nature* **482**, 547-551.
- Hanson, M. A., Roth, C. B., Jo, E., Griffith, M. T., Scott, F. L., Reinhart, G., Desale, H., Clemons, B., Cahalan, S. M., Schuerer, S. C., Sanna, M. G., Han, G. W., Kuhn, P., Rosen, H. & Stevens, R. C. (2012). *Science* **335**, 851-855.
- Hino, T., Arakawa, T., Iwanari, H., Yurugi-Kobayashi, T., Ikeda-Suno, C., Nakada-Nakura, Y., Kusano-Arai, O., Weyand, S., Shimamura, T., Nomura, N., Cameron, A. D., Kobayashi, T., Hamakubo, T., Iwata, S. & Murata, T. (2012). *Nature* **482**, 237-240.
- Hollenstein, K., Kean, J., Bortolato, A., Cheng, R. K., Dore, A. S., Jazayeri, A., Cooke, R. M., Weir, M. & Marshall, F. H. (2013). *Nature* **499**, 438-443.
- Hua, T., Vemuri, K., Nikas, S. P., Laprairie, R. B., Wu, Y., Qu, L., Pu, M., Korde, A., Jiang, S., Ho, J.-H., Han, G. W., Ding, K., Li, X., Liu, H., Hanson, M. A., Zhao, S., Bohn, L. M., Makriyannis, A., Stevens, R. C. & Liu, Z.-J. (2017). *Nature* **547**, 468-471.
- Hua, T., Vemuri, K., Pu, M., Qu, L., Han, G. W., Wu, Y., Zhao, S., Shui, W., Li, S., Korde, A., Laprairie, R. B., Stahl, E. L., Ho, J.-H., Zvonok, N., Zhou, H., Kufareva, I., Wu, B., Zhao, Q., Hanson, M. A., Bohn, L. M., Makriyannis, A., Stevens, R. C. & Liu, Z.-J. (2016). *Cell* **167**, 750-762.

- Huang, J. Y., Chen, S., Zhang, J. J. & Huang, X. Y. (2013). *Nature Structural & Molecular Biology* **20**, 419-425.
- Huang, W., Manglik, A., Venkatakrishnan, A. J., Laeremans, T., Feinberg, E. N., Sanborn, A. L., Kato, H. E., Livingston, K. E., Thorsen, T. S., Kling, R. C., Granier, S., Gmeiner, P., Husbands, S. M., Traynor, J. R., Weis, W. I., Steyaert, J., Dror, R. O. & Kobilka, B. K. (2015). *Nature* **524**, 315-321.
- Isberg, V., Mordalski, S., Munk, C., Rataj, K., Harpsøe, K., Hauser, A. S., Vroiling, B., Bojarski, A. J., Vriend, G. & Gloriam, D. E. (2016). *Nucl. Acids. Res.* **44**, D356-D364.
- Ishchenko, A., Wacker, D., Kapoor, M., Zhang, A., Han, G. W., Basu, S., Patel, N., Messerschmidt, M., Weierstall, U., Liu, W., Katritch, V., Roth, B. L., Stevens, R. C. & Cherezov, V. (2017). *Proc Natl Acad Sci U S A* **114**, 8223-8228.
- Jaakola, V. P., Griffith, M. T., Hanson, M. A., Cherezov, V., Chien, E. Y., Lane, J. R., Ijzerman, A. P. & Stevens, R. C. (2008). *Science* **322**, 1211-1217.
- Janin, J. (1997). *Nat. Struct. Biol.* **4**, 973-974.
- Jastrzebska, B., Comar, W. D., Kaliszewski, M. J., Skinner, K. C., Torcasio, M. H., Esway, A. S., Jin, H., Palczewski, K. & Smith, A. W. (2016). *Biochemistry* **56**, 61-72.
- Jastrzebska, B., Ringler, P., Lodowski, D. T., Molseenkova-Bell, V., Golczak, M., Müller, S. A., Palczewski, K. & Engel, A. (2011). *J. Struct. Biol* **176**, 387-394.
- Jastrzebska, B., Ringler, P., Palczewski, K. & Engel, A. (2013). *J. Struct. Biol.* **182**, 164-172.
- Jazayeri, A., Dore, A. S., Krishnamurthy, H., Southall, S. M., Haig, A. S., Bortolato, A., Koglin, M., Robertson, N. J., Errey, J. C., Andrews, S. P., Teobald, I., Brown, A. J. H., Cooke, R. M., Weir, M. & Marshall, F. H. (2016). *Nature* **533**, 274-277.
- Jazayeri, A., Rappas, M., Brown, A. J. H., Kean, J., Errey, J. C., Robertson, N. J., Fiez-Vandal, C., Andrews, S. P., Congreve, M., Bortolato, A., Mason, J. S., Baig, A. H., Teobald, I., Dore, A. S., Weir, M., Cooke, R. M. & Marshall, F. H. (2017). *Nature* **546**, 254-258.
- Kasai, R. S. & Kusumi, A. (2014). *Curr. Opin. Cell Biol.* **27**, 78-86.
- Katritch, V., Cherezov, V. & Stevens, R. C. (2013). *Annu. Rev. Pharmacol. Toxicol.* **53**, 531-556.

- Kraulis, P. J. (1991). *J. Appl. Crystallogr.* **24**, 946-950.
- Krissinel, E. & Henrick, K. (2004). *Acta Cryst.* **D60**, 2256-2268.
- Krumm, B. E., Lee, S., Bhattacharya, S., Botos, I., White, C. F., Du, H., Vaidehi, N. & Grisshammer, R. (2016). *Scientific Reports* **6**, 38564
- Krumm, B. E., White, J. F., Shah, P. & Grisshammer, R. (2015). *Nat Commun* **6**, 7895.
- Kruse, A. C., Hu, J., Pan, A. C., Arlow, D. H., Rosenbaum, D. M., Rosemond, E., Green, H. F., Liu, T., Chae, P. S., Dror, R. O., Shaw, D. E., Weis, W. I., Wess, J. & Kobilka, B. K. (2012). *Nature* **482**, 552-556.
- Lebon, G., Edwards, P. C., Leslie, A. G. & Tate, C. G. (2015). *Mol Pharmacol* **87**, 907-915.
- Lebon, G., Warne, T., Edwards, P. C., Bennett, K., Langmead, C. J., Leslie, A. G. & Tate, C. G. (2011). *Nature* **474**, 521-525.
- Lee, B. & Richards, F. M. (1971). *J. Mol. Biol.* **55**, 379-400.
- Leslie, A. G. W., Warne, T. & Tate, C. G. (2015). *Nature Structural & Molecular Biology* **22**, 941-942.
- Liang, Y., Fotiadis, D., Filipek, S., Saperstein, D. A., Palczewski, K. & Engel, A. (2003). *J Biol Chem* **278**, 21655-21662.
- Liu, X., Ahn, S., Kahsai, A. W., Meng, K.-C., Latorraca, N. R., Pani, B., Venkatakrishnan, A. J., Masoudi, A., Weis, W. I., Dror, R. O., Chen, X., Lefkowitz, R. J. & Kobilka, B. (2017). *Nature* **548**, 480-484.
- Lu, J., Byrne, N., Wang, J., Bricogne, G., Brown, F. K., Chobanian, H. R., Colletti, S. I., Di Salvo, J., Thomas-Fowlkes, B., Guo, Y., Hall, D. L., Hadix, J., Hastings, N. B., Hermes, J. D., Ho, T., Howard, A. D., Josien, H., Kornienko, M., Lumb, K. J., Miller, M. W., Patel, S. B., Pio, B., Plummer, C. W., Sherborne, B. S., Sheth, P., Souza, S., Tummala, S., Vonnrhein, C., Webb, M., Allen, S. J., Johnston, J. M., Weinglass, A. B., Sharma, S. & Soisson, S. M. (2017). *Nature Structural & Molecular Biology* **24**, 570-577.

- Ma, Y., Yue, Y., Ma, Y., Zhang, Q., Zhou, Q., Song, Y., Shen, Y., Li, X., Ma, X., Li, C., Hanson, M. A., Han, G. W., Sickmier, E. A., Swaminath, G., Zhao, S., Stevens, R. C., Hu, L. A., Zhong, W., Zhang, M. & Xu, F. (2017). *Structure* **25**, 858-866.
- Manglik, A., Kruse, A. C., Kobilka, T. S., Thian, F. S., Mathiesen, J. M., Sunahara, R. K., Pardo, L., Weis, W. I., Kobilka, B. K. & Granier, S. (2012). *Nature* **485**, 321-326.
- McRee, D. E. (1999). *J. Structural Biology*. **125**, 156-165.
- Merritt, E. A. & Bacon, D. J. (1997). *Meth. Enzym.* **277**, 505-524.
- Miller-Gallacher, J. L., Nehme, R., Warne, T., Edwards, P. C., Schertler, G. F., Leslie, A. G. & Tate, C. G. (2014). *PLOS One* **9**, e92727.
- Miller, R. L., Thompson, A. A., Trapella, C., Guerrini, R., Malfacini, D., Patel, N., Han, G. W., Cherezov, V., Calo, G., Katritch, V. & Stevens, R. C. (2015). *Structure* **23**, 2291-2299.
- Moukhametzianov, R., Warne, T., Edwards, P. C., Serrano-Vega, M. J., Leslie, A. G., Tate, C. G. & Schertler, G. F. (2011). *Proc Natl Acad Sci U S A* **108**, 8228-8232.
- Murakami, M. & Kouyama, T. (2008). *Nature* **453**, 363-367.
- Okada, T. (2012). *PLoS ONE* **7**, e35802.
- Okada, T., Sugihara, M., Bondar, A.-N., Elstner, M., Entel, P. & Buss, V. (2004). *J. Mol. Biol.* **343**, 571-583.
- Oswald, C., Rappas, M., Kean, J., Dore, A. S., Errey, J. C., Bennett, K., Deflorian, F., Christopher, J. A., Jazayeri, A., Mason, J. S., Congreve, M., Cooke, R. M. & Marshall, F. H. (2016). *Nature* **540**, 462-465.
- Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Le Trong, I., Teller, D. C., Okada, T., Stenkamp, R. E., Yamamoto, M. & Miyano, M. (2000). *Science* **289**, 739-745.
- Palczewski, K. & Orban, T. (2013). *Annu. Rev. Neurosci.* **36**, 139-164.
- Piscitelli, C. L., Kean, J., de Graaf, C. & Deupi, X. (2015). *Mol. Pharmacol.* **88**, 536-551.
- Qin, L., Kufareva, I., Holden, L. G., Wang, C., Zheng, Y., Zhao, C., Fenalti, G., Wu, H., Han, G. W., Cherezov, V., Abagyan, R., Stevens, R. C. & Handel, T. M. (2015). *Science* **347**, 1117-1122.

- Rasmussen, S. G., Choi, H. J., Fung, J. J., Pardon, E., Casarosa, P., Chae, P. S., Devree, B. T., Rosenbaum, D. M., Thian, F. S., Kobilka, T. S., Schnapp, A., Konetzki, I., Sunahara, R. K., Gellman, S. H., Pautsch, A., Steyaert, J., Weis, W. I. & Kobilka, B. K. (2011). *Nature* **469**, 175-180.
- Rasmussen, S. G., Choi, H. J., Rosenbaum, D. M., Kobilka, T. S., Thian, F. S., Edwards, P. C., Burghammer, M., Ratnala, V. R., Sanishvili, R., Fischetti, R. F., Schertler, G. F., Weis, W. I. & Kobilka, B. K. (2007). *Nature* **450**, 383-387.
- Rasmussen, S. G., DeVree, B. T., Zou, Y., Kruse, A. C., Chung, K. Y., Kobilka, T. S., Thian, F. S., Chae, P. S., Pardon, E., Calinski, D., Mathiesen, J. M., Shah, S. T., Lyons, J. A., Caffrey, M., Gellman, S. H., Steyaert, J., Skinotitis, G., Weis, W. I., Sunahara, R. K. & Kobilka, B. K. (2011). *Nature* **477**, 549-555.
- Ring, A. M., Manglik, A., Kruse, A. C., Enos, M. D., Weis, W. I., Garcia, K. C. & Kobilka, B. K. (2013). *Nature* **502**, 575-579.
- Rosenbaum, D. M., Zhang, C., Lyons, J. A., Holl, R., Aragao, D., Arlow, D. H., Rasmussen, S. G., Choi, H. J., Devree, B. T., Sunahara, R. K., Chae, P. S., Gellman, S. H., Dror, R. O., Shaw, D. E., Weis, W. I., Caffrey, M., Gmeiner, P. & Kobilka, B. K. (2011). *Nature* **469**, 236-240.
- Saff, E. B. & Kuijlaars, A. B. J. (1997). *The Mathematical Intelligencer* **19**, 5-11.
- Salom, D., Lodowski, D. T., Stenkamp, R. E., Le Trong, I., Golczak, M., Jastrzebska, B., Harris, T., Ballesteros, J. A. & Palczewski, K. (2006). *Proc. Natl. Acad. Sci. U.S.A.* **103**, 16123-16128.
- Sato, T., Kawasaki, T., Mine, S. & Matsumura, H. (2016). *Int. J. Mol. Sci.* **17**, ijms17111930.
- Shao, Z., Yin, J., Chapman, K., Grzemska, M., Clark, L., Wang, J. & Rosenbaum, D. M. (2016). *Nature* **540**, 602-606.
- Shihoya, W., Nishizawa, T., Okuta, A., Tani, K., Dohmae, N., Fujiyoshi, Y., Nureki, O. & Doi, T. (2016). *Nature* **537**, 363-368.
- Shihoya, W., Nishizawa, T., Yamashita, K., Inoue, A., Hirata, K., Kadji, F. M. N., Okuta, A., Tani, K., Aoki, J., Fujiyoshi, Y., Doi, T. & Nureki, O. (2017). *Nature Structural & Molecular Biology* **24**, 758-764.
- Shimamura, T., Hiraki, K., Takahashi, N., Hori, T., Ago, H., Masuda, K., Takio, K., Ishiguro, M. & Miyano, M. (2008). *J Biol Chem* **283**, 17753-17756.

- Shimamura, T., Shiroishi, M., Weyand, S., Tsujimoto, H., Winter, G., Katritch, V., Abagyan, R., Cherezov, V., Liu, W., Han, G. W., Kobayashi, T., Stevens, R. C. & Iwata, S. (2011). *Nature* **475**, 65-70.
- Siu, F. Y., He, M., de Graaf, C., Han, G. W., Yang, D., Zhang, Z., Zhou, C., Xu, Q., Wacker, D., Joseph, J. S., Liu, W., Lau, J., Cherezov, V., Katritch, V., Wang, M. W. & Stevens, R. C. (2013). *Nature* **499**, 444-449.
- Song, G., Yang, D., Wang, Y., De Graff, C., Q., Z., Jiang, S., Liu, K., Cai, X., Dai, A., Lin, G., Liu, D., Wu, F., Wu, Y., Zhao, S., Ye, L., Han, G. W., Lau, J., Wu, B., Hanson, M. A., Liu, Z.-J., Wang, M.-W. & Stevens, R. C. (2017). *Nature* **546**, 312-315.
- Staus, D. P., Strachan, R. T., Manglik, A., Pani, B., Kahsai, A. W., Kim, T. H., Wingler, L. M., Ahn, S., Chatterjee, A., Masoudi, A., Kruse, A. C., Pardon, E., Steyaert, J., Weis, W. I., Prosser, R. S., Kobilka, B. K., Costa, T. & Lefkowitz, R. J. (2016). *Nature* **535**, 448-452.
- Stenkamp, R. E. (2008). *Acta Crystallogr D Biol Crystallogr* **D64**, 902-904.
- Sun, B., Bachhawat, P., Chu, M. L.-H., Wood, M., Ceska, T., Sands, Z. A., Mercier, J., Lebon, F., Kobilka, T. S. & Kobilka, B. K. (2017). *Proc Natl Acad Sci U S A* **114**, 2066-2071.
- Tan, Q., Zhu, Y., Li, J., Chen, Z., Han, G. W., Kufareva, I., Li, T., Ma, L., Fenalti, G., Zhang, W., Xie, X., Yang, H., Jiang, H., Cherezov, V., Liu, H., Stevens, R. C., Zhao, Q. & Wu, B. (2013). *Science* **341**, 1387-1390.
- Taniguchi, R., Inoue, A., Sayama, M., Uwamizu, A., Yamashita, K., Hirata, K., Yoshida, M., Tanaka, Y., Kato, H. E., Nakada-Nakura, Y., Otani, Y., Nishizawa, T., Doi, T., Ohwada, T., Ishitani, R., Aoki, J. & Nureki, O. (2017). *Nature* **548**, 356-360.
- Thal, D. M., Sun, B., Feng, D., Nawaratne, V., Leach, K., Felder, C. C., Bures, M. G., Evans, D. A., Weis, W. I., Bachhawat, P., Kobilka, T. S., Sexton, P. M., Kobilka, B. K. & Christopoulos, A. (2016). *Nature* **531**, 335-340.
- Thorsen, T. S., Matt, R., Weis, W. I. & Kobilka, B. K. (2014). *Structure* **22**, 1657-1664.
- Tian, H., Fürstenberg, A. & Huber, T. (2017). *Chem. Rev.* **117**, 186-245.
- Vischer, H. F., Castro, M. & Pin, J. P. (2015). *Mol. Pharmacol.* **88**, 561-571.

Wacker, D., Wang, C., Katritch, V., Han, G. W., Huang, X. P., Vardy, E., McCorvy, J. D., Jiang, Y., Chu, M., Siu, F. Y., Liu, W., Xu, H. E., Cherezov, V., Roth, B. L. & Stevens, R. C. (2013). *Science* **340**, 615-619.

Wang, C., Jiang, Y., Ma, J., Wu, H., Wacker, D., Katritch, V., Han, G. W., Liu, W., Huang, X. P., Vardy, E., McCorvy, J. D., Gao, X., Zhou, X. E., Melcher, K., Zhang, C., Bai, F., Yang, H., Yang, L., Jiang, H., Roth, B. L., Cherezov, V., Stevens, R. C. & Xu, H. E. (2013). *Science* **340**, 610-614.

Wang, C., Wu, H., Evron, T., Vardy, E., Han, G. W., Huang, X. P., Hufeisen, S. J., Mangano, T. J., Urban, D. J., Katritch, V., Cherezov, V., Caron, M. G., Roth, B. L. & Stevens, R. C. (2014). *Nat Commun* **5**, 4355.

Wang, C., Wu, H., Katritch, V., Han, G. W., Huang, X. P., Liu, W., Siu, F. Y., Roth, B. L., Cherezov, V. & Stevens, R. C. (2013). *Nature* **497**, 338-343.

Wang, S., Wacker, D., Levit, A., Che, T., Betz, R. M., McCorvy, J. D., Venkatakrishnan, A. J., Huang, X.-P., Dror, R. O., Shoichet, B. K. & Roth, B. L. (2017). *Science* **358**, 381-386.

Warne, T., Edwards, P. C., Leslie, A. G. & Tate, C. G. (2012). *Structure* **20**, 841-849.

Warne, T., Serrano-Vega, M. J., Baker, J. G., Moukhametzianov, R., Edwards, P. C., Henderson, R., Leslie, A. G., Tate, C. G. & Schertler, G. F. (2008). *Nature* **454**, 486-491.

Weierstall, U., James, D., Wang, C., White, T. A., Wang, D., Liu, W., Spence, J. C., Bruce Doak, R., Nelson, G., Fromme, P., Fromme, R., Grotjohann, I., Kupitz, C., Zatsepin, N. A., Liu, H., Basu, S., Wacker, D., Han, G. W., Katritch, V., Boutet, S., Messerschmidt, M., Williams, G. J., Koglin, J. E., Marvin Seibert, M., Klinker, M., Gati, C., Shoeman, R. L., Barty, A., Chapman, H. N., Kirian, R. A., Beyerlein, K. R., Stevens, R. C., Li, D., Shah, S. T., Howe, N., Caffrey, M. & Cherezov, V. (2014). *Nat Commun* **5**, 3309.

Weinert, T., Olieric, N., Cheng, R. K., Brunle, S., James, D., Ozerov, D., Gashi, D., Vera, L., Marsh, M., Jaeger, K., Dworkowski, F. S. N., Panepucci, E., Basu, S., Skopintsev, P., Dore, A. S., Geng, T., Cooke, R. M., Liang, M., Prota, A. E., Panneels, V., Nogly, P., Ermler, U., Schertler, G., Hennig, M., Steinmetz, M. O., Wang, M. & Standfuss, J. (2017). *Nature Communications*.

White, J. F., Noinaj, N., Shibata, Y., Love, J., Kloss, B., Xu, F., Gvozdenovic-Jeremic, J., Shah, P., Shiloach, J., Tate, C. G. & Grisshammer, R. (2012). *Nature* **490**, 508-513.

Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., McNicholas, S. J., Murshudov, G. N., Pannu, N. S., Potterton, E. A., Powell, H. R., Read, R. J., Vagin, A. & Wilson, K. S. (2011). *Acta Cryst.* **D67**, 235-242.

Wu, B., Chien, E. Y., Mol, C. D., Fenalti, G., Liu, W., Katritch, V., Abagyan, R., Brooun, A., Wells, P., Bi, F. C., Hamel, D. J., Kuhn, P., Handel, T. M., Cherezov, V. & Stevens, R. C. (2010). *Science* **330**, 1066-1071.

Wu, H., Wacker, D., Mileni, M., Katritch, V., Han, G. W., Vardy, E., Liu, W., Thompson, A. A., Huang, X. P., Carroll, F. I., Mascarella, S. W., Westkaemper, R. B., Mosier, P. D., Roth, B. L., Cherezov, V. & Stevens, R. C. (2012). *Nature* **485**, 327-332.

Wu, H., Wang, C., Gregory, K. J., Han, G. W., Cho, H. P., Xia, Y., Niswender, C. M., Katritch, V., Meiler, J., Cherezov, V., Conn, P. J. & Stevens, R. C. (2014). *Science* **344**, 58-64.

Yin, J., Babaoglu, K., Brautigam, C. A., Clark, L., Shao, Z., Scheuermann, T. H., Harrell, C. M., Gotter, A. L., Roecker, A. J., Winrow, C. J., Renger, J. J., Coleman, P. J. & Rosenbaum, D. M. (2016). *Nat Struct Mol Biol* **23**, 293-299.

Yin, J., Mobarec, J. C., Kolb, P. & Rosenbaum, D. M. (2015). *Nature* **519**, 247-250.

Zhang, C., Srinivasan, Y., Arlow, D. H., Fung, J. J., Palmer, D., Zheng, Y., Green, H. F., Pandey, A., Dror, R. O., Shaw, D. E., Weis, W. I., Coughlin, S. R. & Kobilka, B. K. (2012). *Nature* **492**, 387-392.

Zhang, D., Gao, Z. G., Zhang, K., Kiselev, E., Crane, S., Wang, J., Paoletta, S., Yi, C., Ma, L., Zhang, W., Han, G. W., Liu, H., Cherezov, V., Katritch, V., Jiang, H., Stevens, R. C., Jacobson, K. A., Zhao, Q. & Wu, B. (2015). *Nature* **520**, 317-321.

Zhang, H., Han, G. W., Batyuk, A., Ishchenko, A., While, K. L., Patel, N., Sadybekov, A., Zamlenny, B., Rudd, M. T., Hollenstein, K., Tolstikova, A., White, T. A., Hunter, M. S., Weierstall, U., Liu, W., Babaoglu, K., Moore, E. L., Katz, R. D., Shipman, J. M., Garcia-Calvo, M., Sharma, S., Sheth, P., Soisson, S. M., Stevens, R. C., Katritch, V. & Cherezov, V. (2017). *Nature* **544**, 327-332.

Zhang, H., Qiao, A., Yang, D., Yang, L., Dai, A., De Graaf, C., Reedtz-Runge, S., Dharmarajan, V., Zhang, H., Han, G. W., Grant, T. D., Sierra, R. G., Weierstall, U., Nelson, G., Liu, W., Wu, Y., Ma, L., Cai, X., Lin, G., Wu, X., Geng, Z., Dong, Y., Song, G., Griffin, P. R., Lau, J., Cherezov, V., Yang, H., Hanson, M. A., Stevens, R. C., Zhao, Q., Jiang, H., Wang, M.-W. & Wu, B. (2017). *Nature* **546**, 259-264.

Zhang, H., Unal, H., Desnoyer, R., Han, G. W., Patel, N., Katritch, V., Karnik, S. S., Cherezov, V. & Stevens, R. C. (2015). *J Biol Chem* **290**, 29127-29139.

Zhang, H., Unal, H., Gati, C., Han, G. W., Liu, W., Zatsepin, N. A., James, D., Wang, D., Nelson, G., Weierstall, U., Sawaya, M. R., Xu, Q., Messerschmidt, M., Williams, G. J., Boutet, S., Yefanov, O. M., White, T. A., Wang, C., Ishchenko, A., Tirupula, K. C., Desnoyer, R., Coe, J., Conrad, C. E., Fromme, P., Stevens, R. C., Katritch, V., Karnik, S. S. & Cherezov, V. (2015). *Cell* **161**, 833-844.

Zhang, J., Zhang, K., Gao, Z. G., Paoletta, S., Zhang, D., Han, G. W., Li, T., Ma, L., Zhang, W., Muller, C. E., Yang, H., Jiang, H., Cherezov, V., Katritch, V., Jacobson, K. A., Stevens, R. C., Wu, B. & Zhao, Q. (2014). *Nature* **509**, 119-122.

Zhang, K., Zhang, J., Gao, Z. G., Zhang, D., Zhu, L., Han, G. W., Moss, S. M., Paoletta, S., Kiselev, E., Lu, W., Fenalti, G., Zhang, W., Muller, C. E., Yang, H., Jiang, H., Cherezov, V., Katritch, V., Jacobson, K. A., Stevens, R. C., Wu, B. & Zhao, Q. (2014). *Nature* **509**, 115-118.

Zhang, X., Zhao, F., Wu, Y., Yang, J., Han, G. W., Zhao, S., Ishchenko, A., Ye, L., Lin, X., Ding, K., Dharmarajan, V., Griffin, P. R., Gati, C., Nelson, G., Hunter, M. S., Hanson, M. A., Cherezov, V., Stevens, R. C., Tan, W., Tao, H. & Xu, F. (2017). *Nature Communications* **8**, 15383.

Zheng, Y., Han, G. W., Abagyan, R., Wu, B., Stevens, R. C., Cherezov, V., Kufareva, I. & Handel, T. M. (2017). *Immunity* **46**, 1005-1017.

Zheng, Y., Qin, L., Ortiz Zacarias, N. V., de Vries, H., Han, G. W., Gustavsson, M., Dabros, M., Zhao, C., Cherney, R. J., Carter, P., Stamos, D., Abagyan, R., Cherezov, V., Stevens, R. C., Uzerman, A. P., Heitman, L. H., Tebben, A., Kufareva, I. & Handel, T. M. (2016). *Nature* **540**, 458-461.

Zhou, X. E., He, Y., De Waal, P. W., Gao, X., Kang, Y., Van Eps, N., Yin, Y., Pal, K., Goswami, D., White, T. A., Barty, A., Latorraca, N. R., Chapman, H. N., Hubbell, W. L., Dror, R. O., Stevens, R. C., Cherezov, V., Gurevich, V. V., Griffin, P. R., Ernst, O. P., Melcher, K. & Xu, H. E. (2017). *Cell* **170**, 457-469.

Zou, Y., Weis, W. I. & Kobilka, B. K. (2012). *PLOS One* **7**, e46039.